LARIAM
LOE ApproachingNDAORALTABLET
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARIAM (mefloquine) is an oral antimalarial agent approved by the FDA in 1989 for prevention and treatment of malaria. The mechanism of action involves disruption of the parasite's ability to form hemozoin, a toxic byproduct of hemoglobin digestion. It is primarily indicated for travelers and at-risk populations requiring malaria prophylaxis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential team downsizing or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARIAM is approaching loss of exclusivity, making it a challenging career assignment for growth-oriented professionals. Roles tied to this product will focus on defending market share, managing generic transition, and optimizing pricing and access strategies rather than expansion.
Brand ManagerField Sales Representative
Worked on LARIAM at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.